In‐hospital mortality at up to day 150 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in in‐hospital mortality at up to day 150 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care probably leads to higher clinical improvement: participants alive and ready to be discharged… compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care probably leads to lower clinical worsening: time to new need for invasive mechanical… compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Serious adverse events at up to day 28 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Intervention not reported
28‐day all‐cause mortality · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention probably leads to lower 28‐day all‐cause mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Worsening up to day 28: participants with new need for invasive mechanical ventilation or death · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in worsening up to day 28: participants with new need for invasive… (moderate certainty).
1 finding from 1 review
Intervention not reported
Improvement up to day 28: participants discharged alive · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in improvement up to day 28: participants discharged alive (moderate certainty).
1 finding from 1 review
Intervention not reported
Thrombotic events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in thrombotic events at longest (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in serious adverse events at longest (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events during study treatment · hospitalised adults with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Major bleeding events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention probably leads to higher major bleeding events at longest (moderate certainty).
1 finding from 1 review
All‐cause mortality at day 28 · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.79 [0.43, 1.44]
Studies not reported
Low
Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in improvement of clinical status (number of participants discharged… compared with saline placebo (low certainty).
1 finding from 1 review
Quality of life · individuals with moderate or severe COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
1 finding from 1 review
OR 4
3 participants
GRADE not reported
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status at day 28 (data only available for clinical status worsened on day 7) · individuals with moderate or severe COVID‐19
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).
1 finding from 1 review
RR 0.85 [0.58, 1.23]
Studies not reported
Very low
Improvement of clinical status · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in improvement of clinical status (number of people discharged from… compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 1.02 [0.97, 1.08]
Studies not reported
Moderate